References in periodicals archive ?
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/ refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Launched in the UK in August 2016, CALM is an open label, dose-escalation study designed to evaluate safety, tolerability and antileukemic activity of UCART19 in patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APL, acute promyelocyte leukemia; B- ALL, B-cell acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia.
BioCryst also plans to initiate a Phase I/II trial in B-cell acute lymphoblastic leukemia during the first half of 2005.
The positive opinion includes two B-cell malignancies: B-cell acute lymphoblastic leukemia that is refractory, in relapse post-transplant or in second or later relapse in patients up to 25 years of age; and diffuse large B-cell lymphoma that is relapsed or refractory after two or more lines of systemic therapy in adults.
The CALM study is an open label, dose-escalation study designed to evaluate safety, tolerability and antileukemic activity of UCART19 in adult patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia.
In addition, the European Medicines Agency has granted accelerated assessment to the Marketing Authorization Application for Kymriah for the treatment of children and young adults with r/r B-cell acute lymphoblastic leukemia, or ALL, and for adult patients with r/r DLBCL who are ineligible for ASCT.
27 June 2014 - US genomic immune profiling specialist Adaptive Biotechnologies Corp reported Friday study data showing that its clonoSEQ assay had better accuracy and sensitivity in detecting risk of relapse in patients with B-cell acute lymphoblastic leukemia (B-ALL), versus the current standard of care lab test.
Acronyms browser ?
Full browser ?
- B-B shot pulse
- b-c fracture
- B-c meson
- b-c plane
- b-carotene 15,15-dioxygenase
- B-cell Acute Lymphoblastic Leukemia
- B-Cell Acute Lymphoblastic Leukemia Expressed
- B-Cell Adhesion Molecule
- B-cell chemoattractant
- B-Cell Chronic Lymphocytic Leukemia
- B-Cell Cll/Lymphoma
- B-cell CLL/lymphoma 1
- B-cell CLL/lymphoma 10
- B-Cell CLL/Lymphoma 2
- B-cell CLL/lymphoma 3
- B-cell CLL/lymphoma 6
- B-cell CLL/lymphoma 7 protein family member A
- B-cell CLL/lymphoma 7 protein family member B
- B-cell CLL/lymphoma 7 protein family member C
- B-cell CLL/lymphoma 7A
- B-cell CLL/lymphoma 7B
- B-cell CLL/lymphoma 7C
- B-cell CLL/lymphoma 8
- B-cell CLL/lymphoma 9
- B-cell CLL/lymphoma 9 protein
- B-cell CLL/lymphoma-7
- B-cell co-receptor
- B-cell coreceptor
- B-cell differentiating factor
- B-cell differentiating factor
- B-cell differentiation factor
- B-cell differentiation factor I
- B-cell differentiation/growth factors
- B-cell differentiationgrowth factors
- B-Cell Diffuse Large Cell Lymphoma
- B-Cell Growth and Differentiation Factor